Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.40 |
| ▸ | LOX | P28300 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.38 |
| ▸ | FEN1 | P39748 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9256967 | 0.79 | P2RX7 (0.39) | P2RX7RXRAHTR1AGRIN1GRIN2B | |
| SCHEMBL31608506 | 0.79 | GRM5 (0.50) | P2RX7RXRAKDM4EGRIN1GRIN2B | |
| SCHEMBL13064185 | 0.79 | GRM5 (0.50) | P2RX7RXRAKDM4EGRIN1GRIN2B | |
| SCHEMBL13278266 | 0.76 | NUDT1 (0.47) | P2RX7RXRAGRIN1GRIN2BGRM5 | |
| Hydrochloric Acid SCHEMBL19743607 | 0.75 | KDM4E (0.44) | HTR1BHTR1ATAAR1KDM4EHTR7 | |
| SCHEMBL5560493 | 0.75 | POLB (0.38) | P2RX7RXRAGRIN1GRIN2BGRM5 | |
| SCHEMBL19534932 | 0.74 | P2RX7 (0.41) | P2RX7LOXL2LOXALOX5APFEN1 | |
| SCHEMBL22397018 | 0.73 | KMT2A (0.46) | P2RX7LOXL2KDM4E | |
| SCHEMBL32682038 | 0.73 | KMT2A (0.46) | P2RX7LOXL2KDM4E | |
| SCHEMBL13822632 | 0.73 | HTR1B (0.42) | HTR1BHTR1ATAAR1KDM4EHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563073-B | For the treatment of para-5-HT1AReceptor-controlled serotonergic disease-modulating compounds | 诺罗利西斯公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-3475268-B9 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2021-04-21 | — | — | EP | disclosed |
| EP-3475268-B1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2020-08-19 | — | — | EP | disclosed |
| US-10562853-B2 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors | NEUROLIXIS (FR) | 2020-02-18 | — | — | US | disclosed |
| US-20190194132-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2019-06-27 | — | — | US | disclosed |
| EP-3475268-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | Neurolixis (FR) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017220799-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562853-B2 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors | HTR5A, HTR1A, HTR1E | P2RX7 225/4885LOXL2 4438/4885LOX 3962/4885 |
| US-20190194132-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | HTR5A, HTR1A, HTR1E | P2RX7 225/4885LOXL2 4438/4885LOX 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.